QPCT (glutaminyl-peptide cyclotransferase) is bound to HRAS and improves the stability of HRAS by inhibiting its ubiquitination degradation, which can activate the ERK signaling pathway and lead to sunitinib resistance in renal cell cancer[32]. This evidence concerns the gene QPCT and renal cell adenocarcinoma.